oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial SELECT Trial

As a GLP-1 agonist medication, semaglutide mimics GLP-1 a natural hormone released by your pancreas after you eat

Leading Companies Delivering GLP-1 Nutritional Support Solutions Leading Company - Nestl Health Science Industry Share - 18% In the GLP-1 nutritional support market, leading players are leveraging clinical positioning, micronutrient optimization, and bariatric-friendly formats to target consumers on GLP-1 therapies such as semaglutide and tirzepatide

Healthcare providers may recommend periodic evaluations of cardiovascular health, kidney function, and overall well-being

What birth control options are good alternatives while on GLP-1s

This article explores the specific timelines for medication longevity, the difference between various dating methods, and how to ensure your treatment remains as effective as possible

About one in eight adults say they have taken the drugs, according to a KFF poll released in the spring